In Vivo Pharmacological Evaluations of Novel Olanzapine Analogues in Rats: A Potential New Avenue for the Treatment of Schizophrenia

Abstract

Olanzapine (Olz) is one of the most effective antipsychotic drugs commonly used for treating schizophrenia. Unfortunately, Olz administration is associated with severe weight gain and metabolic disturbances. Both patients and clinicians are highly interested in the development of new antipsychotics which are as effective as atypical antipsychotics but which have a lower propensity to induce metabolic side effects. In the present study, we examined two new derivatives of Olz; OlzEt (2-ethyl-4-(4′-methylpiperazin-1′-yl)-10Hbenzo[b]thieno[2,3-e][1,4]diazepine), and OlzHomo (2-ethyl-4-(4′-methyl-1′,4′-diazepan-1′-yl)-10H-benzo[b]thieno[2,3-e] [1,4]diazepine), for their tendency to induce weight gain in rats. Weight gain and metabolic changes were measured in female Sprague Dawley rats. Animals were treated orally with Olz, OlzEt, OlzHomo (3 or 6 mg/kg/day), or vehicle (n = 8), three times daily at eight-hour intervals for 5 weeks. Furthermore, a phencyclidine (PCP)-treated rat model was used to examine the prevention of PCP-induced hyperlocomotor activity relevant for schizophrenia therapy. Male Sprague Dawley rats were pre-treated with a single dose (3 mg/kg/day) of Olz, OlzEt, OlzHomo, or vehicle (n = 12), for 2 weeks. Locomotor activity was recorded following a subcutaneous injection with either saline or PCP (10 mg/kg). Olz was found to induce weight gain, hyperphagia, visceral fat accumulation, and metabolic changes associated with reduced histamatergic H1 receptor density in the hypothalamus of treated rats. In contrast, OlzEt and OlzHomo presented promising antipsychotic effects, which did not induce weight gain or fat deposition in the treated animals. Behavioural analysis showed OlzEt to attenuate PCP-induced hyperactivity to a level similar to that of Olz; however, OlzHomo showed a lower propensity to inhibit these stereotyped behaviours. Our data suggest that the therapeutic effectiveness of OlzHomo may be delivered at a higher dose than that of Olz and OlzEt. Overall, OlzEt and OlzHomo may offer a better pharmacological profile than Olz for treating patients with schizophrenia. Clinical trials are needed to test this hypothesis.

Antroquinonol administration in animal preclinical studies for Alzheimer's disease (AD): A new avenue for modifying progression of AD pathophysiology

“…Object recognition testing was performed after habituation to an open-field box and according to a protocol previously described ( Fernandez et al., 2012 ; Jafari et al., 2013 ). An objection recognition (OR) test, corresponding to the ratio of the amount of time spent exploring the novel object over the total time spent exploring both objects, was used to assess learning and memory function.…”

“…Performance in the spontaneous alternation task was also assessed using a Y-maze as previously described ( Jafari et al., 2013 ). Testing was for 10 free-choice arm entries or 16 ​min, whichever occurred first.…”

Exploring the kinetic selectivity of antipsychotics for dopamine D2 and 5-HT2A receptors: implications for the prevalence of EPS and receptor occupancy

“…To achieve a fair comparison, we considered differences in cortical 5-HT 2A R density relative to striatal D 2 R receptor density. Previous human and animal studies indicate that 5-HT 2A R numbers are at least 2-3 times greater in the (prefrontal) cortex relative to the striatum (Jafari et al, 2013; Joyce et al, 1991; Muguruza et al, 2013).…”

“…Previous human and animal studies indicate that 5-HT 2A R numbers are at least 2-3 times greater in the (prefrontal) cortex relative to the striatum (Jafari et al, 2013;Joyce et al, 1991;Muguruza et al, 2013).…”

Eco-friendly synthesis of new olanzapine derivatives and evaluation of their anticancer potential

“…[10][11][12][13][14] Additionally, it has also been tested in patients with Anorexia Nervosa. [15][16][17] These numerous advantages of olanzapine prompted scientists to search for olanzapine derivatives, which are tested, for example, as selective ligands of 5HT 2A /D 2 receptors for more effective treatment of schizophrenia 18,19 as PDE4B inhibitors. This means the derivatives can have procognitive, neuroprotective, and anti-inammatory effects.…”